Five companies that have defied the gloom, and are set to do even better once the Indian growth story resumes
There is scope for more improvement in profitability, given the gap between the company and the big 4
Many of India's top companies now rival their global peers in scale of operations, but remain pygmies on key financial parameters
Rising share of engineering goods, pharma at expense of traditionals such as textiles, gems & jewellery
May depreciate but at slower pace than emerging market peers
Sun Pharma is now India's largest drug maker and among the ten most valuable pharma companies globally
The net profit of Sensex companies is up 23% and 14 out of 18 companies having beaten the earnings estimates
In last ten years automobile and pharma exports have grown at a CAGR of 30% and 22% respectively
Net sales zoom 28% to Rs 15,981 cr
Over 10 years, Tata group companies' investment in fixed assets increases at 24% CAGR; non-banking & financial PSUs' rises at 10.8%
Net profit of 82 firms up 20.2%, but topline growth slows to 14.7% on muted show by manufacturing firms
In five years, royalty payments have grown 31.1% yearly, much faster than rise in revenue and profit
The post-1991 economic boom was accompanied by a reduction in indirect taxes and rise in the share of direct taxes, and vice versa in the current slowing
In last ten years, India's import bill grew at a CAGR of 23% against 20% growth in IT exports and dollar remittances during the period
Putting money in key PSUs a better option
Barring one, three debt-free and sitting on large cash reserves
IT, pharma and auto likely to drive earnings growth in the third quarter; banking, oil & gas and capital goods to be a drag
Markets lack the fuel for a broader rally but you can still make money in 2014, if you select the right stocks and hold on to these for some time
Interview with Founder & Managing Director Sun Pharmaceutical
Tata group's market value is up 38% against the 9% rise in the Sensex in the past 12 months